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FRANCE, C. P., J. U. ADAMS AND J. H. WOODS. Intracerebroventricular drug administration in pigeons. PHAR- 
MACOL B1OCHEM BEHAV 23(5) 731-736, 1985.-For many procedures used in behavioral pharmacology, the intracer- 
ebroventricular (ICV) route of drug administration is infrequently used due, in part, to the lack of a reliable technique for 
determining cannula patency in vivo. This study describes an in vivo technique for assessing ICV cannula patency in 
pigeons. The technique was applied in an experiment designed to evaluate several drugs, which are presumed to differ in 
the extent to which they enter the central nervous system, for their rate-suppressing effects in pigeons trained to peck a key 
on a fixed-ratio 20 schedule of food reinforcement. The opioid agonist morphine and antagonist quaternary naltrexone were 
100 and 280 times more potent, respectively, in suppressing responding when administered ICV, as compared to systemic 
administration. Tertiary naltrexone was approximately equipotent as an antagonist of morphine's rate-suppressing effects 
when administered ICV or systemically. Quaternary naltrexone did not antagonize morphine by either route of administra- 
tion. The utility of this in vivo cannula verification technique is discussed, as well as the limitations of comparisons between 
systemically-administered tertiary and quaternary derivatives. 
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SEVERAL strategies have been used for examining the im- 
portance of central and peripheral mechanisms of phar- 
macological effects in vivo. A marked difference in the po- 
tency of a compound when administered centrally and pe- 
ripherally can indicate the relative importance of central and 
peripheral mechanisms. In rats, for example, the analgesic 
[3, 13, 14], discriminative [6,18], rate-suppressant [2], and 
locomotor-increasing [1] effects of opioid agonists (e.g., 
morphine) occur with much smaller doses when these drugs 
are administered directly into the central nervous system 
(CNS) as compared to the doses needed to induce these 
effects after systemic administration. Thus, these effects of 
opioids are mediated predominantly by central mechanisms. 
Comparisons of the behavioral effects of systemically- 
administered tertiary and quaternary derivatives of drugs 
have also been used as indices of central and peripheral 
mechanism. Quaternization of the opioid antagonist nal- 
trexone, for example, does not markedly affect its ability to 
displace [:~H]etorphine from rat brain membranes or its abil- 
ity to antagonize morphine's inhibitory effects on the guine a 
pig ileum [19]. However, in most, but not all [5, 12, 17] in 
vivo experiments neither quaternary opioid antagonists [5, 
16, 19] nor quaternary opioid agonists [11] mimic the actions 
of their respective tertiary forms when administered system- 
ically. Given the similar spectrum of action of quaternary 
and tertiary naltrexone in vitro, and the marked differences 
in the effects of these compounds when administered sys- 
temically in vivo, it is generally assumed, for example, that 
the lack of activity displayed by quaternary antagonists in 
vivo is a direct result of their inability to enter the CNS [4]. 
These data have provided presumptive, although not 
conclusive, evidence that the mechanisms responsible for 
many of the actions of opioid agonists and antagonists are 
located within the CNS. More direct evidence can be ob- 
tained from procedures which examine the effects of tertiary 
and quaternary derivatives when given by various routes of 
administration (e.g., [5,9]). To date, most experimental proce- 
dures which involve the administration of drugs directly into 
the CNS are of short duration, and cannula placement can 
only be determined with histological techniques upon termi- 
nation of the experiment. The present study illustrates the 
long-term use of a cannula system in pigeons and the useful- 
ness of a non-invasive radiographic verification procedure; 
relatively little is known about the pharmacological and be- 
havioral significance of the blood-brain barrier (BBB) in the 
pigeon, despite the extensive use of this species within be- 
havioral pharmacology. In addition, some results are de- 
scribed for compounds presumed to have different capacities 
for entering the CNS. The rate-suppressing effects of intra- 
cerebroventricular (ICV) and intramuscular (IM) morphine, 
naltrexone (tertiary), and naltrexone methobromide 
(quaternary naltrexone) were examined, as well as the effec- 
tiveness of ICV and IM naltrexone and quaternary nal- 
trexone in antagonizing the rate-suppressing effects of IM 
morphine. 
~Supported by USPHS Grant DA 00154. Portions of these data were presented at the 92rid Annual Convention of the American Psycholog- 
ical Association, Toronto, August, 1984 [8]. 
~Requests for reprints should be addressed to Charles P. France, Department of Pharmacology, 6322 Medical Science Building I, University 
of Michigan Medical School, Ann Arbor, MI 48109-0010. 
731 
732 FRANCE, ADAMS AND WOODS 
METHOD 
Subjects 
White Carneaux pigeons (Palmetto, Sumter, SC) weigh- 
ing 401-770 g were reduced to 80% of their free-feeding 
weight. The reduced body weight was maintained by food 
earned during experimental sessions and supplemental feed- 
ing in the home cage (mixed grain and Purina Pigeon Check- 
ers) where water and grit were freely available. Twenty-six 
pigeons have been cannulated to date for various experi- 
ments; the data in the present study were obtained with 
eleven pigeons. 
Apparatus 
Experimental sessions were conducted in a ventilated, 
sound-attenuated operant chamber measuring 36 cm high × 
28 cm wide × 33 cm long. Three translucent response keys 
(2.4 cm diameter) were located on the inside of one wall, 
approximately 25 cm from the chamber floor. During periods 
of food availability, the center key was transilluminated 
green by a 7-W light located behind the key. Reinforcement 
consisted of a 4-sec access to mixed grain, made available 
via a hopper that pivoted into an opening in the wall, directly 
below the response key. During reinforcement the key light 
was off and a white light illuminated the hopper. A Texas 
Instruments 960A computer (Texas Instrument, Inc., Dallas, 
TX) and cumulative response recorders (Ralph Gerbrands 
Co., Arlington, MA), located in an adjacent room, were used 
for control of experimental events, data collection, and re- 
cording. 
Surgery 
Pigeons were anaesthetized with 2.5 ml/kg Chloropent 
(chloral hydrate and pentobarbital (Fort Dodge Labora- 
tories, Inc., Fort Dodge, IA)) and 5.0 mg/kg ketamine, and a 
chronic, indwelling guide cannula (8.5 mm in length, 22 g 
stainless steel (Plastic Products, Inc.)) was surgically im- 
planted using stereotaxic procedures and a Revzin adaptor 
[15]. An attempt was made to place the tip of the guide 
cannula directly into the lateral ventricle using the coordi- 
nates: 8.8 mm dorsal and 6.8 mm rostral from the interaural 
axis, and 1.5 mm lateral from the midline (Fig. 1). The can- 
nula was permanently fixed with skull screws and Cranio- 
plastic. 
Following surgery, and once every month thereafter, 
each bird was anaesthetized with 25.0 mg/kg ketamine and 
cannula patency was assessed by radiographs taken im- 
mediately after an ICV injection of 10-20 ~1 (6--12 mg) 
radio-opaque dye (Conray (Mallinckrodt, Inc., St. Louis, 
MO)). A 28 g dummy cannula (Plastic Products, Inc.) was 
inserted into the guide cannula, except during infusions. 
Procedure 
Pigeons were trained to respond on a single key by differ- 
ential food reinforcement of successive approximations of 
the key peck. Experimental sessions were conducted on 
three consecutive days each week, and consisted of five dis- 
crete 15 minute trials. Each trial consisted of a ten minute 
pretreatment period, during which the chamber was dark and 
key pecks had no programmed consequence, and a five 
minute response period, during which reinforcement was 
available on a variable-interval 30 second (VI30") schedule of 
food delivery (i.e., the first response, after an average inter- 
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FIG. 1. A schematic lateral view (sagittal, 1.0 mm from midline) of 
the pigeon brain showing the cannula tract (hatched) and lateral 
ventricle (shaded). (Reproduced with permission from Karten and 
Hodos. 1967, p. 176.) 
val of 30 seconds since the previous food delivery, was rein- 
forced). Prior to each control (i.e., non-test) session, pigeons 
received an injection of saline (1 ml/kg, IM) or sterile water 
(10/zl, ICV). 
Testing 
Tests were conducted once per week, and drug injections 
were given one hour, ten minutes, or immediately before the 
beginning of the test session (see Results section). Systemic 
injections were made to the breast muscle in a volume of 1 
ml/kg body weight. Central injections (injection volume 10 
pJ) were performed manually over a period of one to two 
minutes with a 100 p~l Hamilton syringe connected to a 28 g 
injection cannula (Plastic Products, Inc.) with PE 20 polyeth- 
ylene tubing. The injection cannula was held in place for an 
additional one to two minutes in order to reduce the 
possibility of fluid backflow through the guide cannula. The 
injection cannula protruded 0.5 mm beyond the tip of the 
guide cannula. The order of tests for individual subjects was 
non-systematic. 
In order to determine the rate-suppressing effects of each 
compound, a single injection (ICV or IM) of morphine, nal- 
trexone, or naltrexone methobromide was administered im- 
mediately before the first of five test trials. This multiple-trial 
procedure allowed for evaluation of the time course of rate- 
suppressing effects over a 1]/4 hr session. For tests of antag- 
onism, a single injection (ICV or IM) of naltrexone or nal- 
trexone methobromide was administered ten or 60 minutes 
prior to the beginning of the first test trial. Additionally, a 
dose of 10.0 mg/kg morphine (IM) was administered im- 
mediately before the first trial. The data are expressed as the 
mean percentage of the vehicle (control) response rate _+1 
S.E.M., for four pigeons at each drug condition. 
Drugs 
The drugs used in this experiment were morphine sulfate 
(Mallinckrodt, Inc., St. Louis, MO), naltrexone hydrochlo- 
ride (Endo Laboratories, Inc., Garden City, NY) and hal- 
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FIG. 2. Radiographs taken prior to (left panel) or immediately after (center and right panels) an ICV injection of 10-20/.d 
radio-opaque dye. The pigeons shown in the center and right panels were judged to have a positive and a negative 
cannula placement, respectively. 
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FIG. 3. Dose-effect curves for the rate-suppressing effects oflCV (open symbols) and IM (closed symbols) morphine (left panel), 
tertiary naltrexone (middle panel), and quaternary naltrexone (right panel). Injections were made ten minutes prior to the first of 
five test trials, and each point represents the mean + 1 S.E.M. of four pigeons, for all five trials. Ordinate: mean response rate, 
expressed as a percentage of the saline control rate. Abscissae: dose in milligrams per kilogram body weight. Fixed doses were 
administered 1CV (e.g., 100 p~g), however for display purposes the fixed doses have been converted to mg/kg, 
trexone methobromide (MRZ 2663BR, Dr. H. Merz, C. H. 
Boehringer Sohn, Ingelheim am Rheim Federal Republic of 
Germany). Morphine and naltrexone were dissolved in 
sterile 0.9% saline for systemic administration, and in sterile 
water for central administration. Naltrexone methobromide 
was dissolved in sterile water. 
RESULTS 
C(mnula Verification 
Cannula placement was determined by x-rays in which 
the distribution of radio-opaque dye delineated the ventricu- 
lar horn. Cannula placement was judged to be negative if the 
dye appeared to diffuse to areas other than the ventricular 
space or, more typically, if dye was concentrated only at the 
cannula tip (Fig. 2, right panel). Of 26 surgical attempts to 
date, 19 (73%) have resulted in successful placement of the 
guide cannula tip into the lateral ventricle, as determined by 
diffusion of the dye throughout the lateral ventricle (Fig. 2, 
center panel). Of 19 subjects judged initially to have positive 
cannula placement, four died from causes unrelated to can- 
nulation, two lost their cannula within five months of surgery 
(apparently a result of the cannula being bumped or caught in 
the home cage), four were subsequently judged negative 
after 10.4_+3.2 months (range=2.0-17.5), and nine pigeons 
are still positive after 9.7_+1.1 months (range=4.1-17.0). 
Only data obtained from experiments which were both pre- 
ceded and followed by a positive x-ray were included in the 
analysis. 
Rate-Suppressing £ffects of  Morphine, Naltrexone, and 
Quaternary Naltrexone 
Morphine dose-dependently suppressed food-reinforced 
responding when administered ICV or IM. A dose of 10.0 or 
32.0 mg/kg morphine IM suppressed responding to a mean 
rate of less than 10% of the saline control rate over the five 
trial session, while a dose of 100.0/~g (0.21 mg/kg) ICV was 
required to produce a comparable suppression of rates (Fig. 
3). Thus, morphine was 50--150 times more potent in sup- 
pressing behavior when administered ICV. 
Quaternary naltrexone also suppressed responding by 
both routes of administration. Systemically, 100.0 mg/kg was 
the smallest dose of quaternary naltrexone that reliably sup- 
pressed response rates to less than 10% of the control rate 
(Fig. 3). Administration of 100.0/~g (0.206 mg/kg) quaternary 
120- 
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FIG. 4. The rate-suppressing effects of a single ICV injection of 
320.0/xg tertiary (diamonds) or 56.0/xg quaternary (triangles) nal- 
trexone over a five trial (1 V4 hr) test session. Abscissa: successive 
15 minute trials. Other information as in Fig. 3. 
naltrexone ICV suppressed responding completely over the 
11/4 hour test session and was accompanied by violent shak- 
ing and vomiting. 
Tertiary naltrexone (IM) also suppressed responding 
dose-dependently, and was equipotent to systemically- 
administered quaternary naltrexone (Fig. 3). Although the 
largest ICV dose of tertiary naltrexone that has been eval- 
uated, 560.0 p-g (1.22 mg/kg), suppressed responding par- 
tially in all animals, the mean response rate for the five trial 
session was greater than 50% of the vehicle control rate. 
Higher doses could not be tested because doses of tertiary 
naltrexone greater than 100.0 p-g also induced pronounced, 
although comparatively short-lived, shaking and vomiting. 
The failure of tertiary naltrexone to suppress responding 
completely appeared to be related to the time course of its 
effects. Figure 4 shows the time course for a single ICV 
injection of 320.0 p-g tertiary naltrexone or 56.0 p-g 
quaternary naltrexone. While these doses produced a similar 
degree of rate suppression during the first trial (20-40% of 
control rates), the effects of tertiary naltrexone dissipated 
very rapidly such that responding had recovered completely 
by the fifth trial. Quaternary naltrexone, however, continued 
to suppress rates for the duration of the 11/4 hr test session. 
Larger doses of quaternary naltrexone (i.e., 100.0 p-g) which 
suppressed responding completely on the day of administra- 
tion, also suppressed rates 24 hr later to 41 .5-  + 13.4% of the 
control rate. There were no apparent rate effects 24 hr after 
ICV or IM tertiary naltrexone, or 24 hr after IM quaternary 
naltrexone. 
Antagonism of Morphine's Rate-Suppressing Effects 
The potency of tertiary naltrexone in antagonizing the 
rate-suppressing effects of 10.0 mg/kg morphine IM was ap- 
proximately the same by the two routes of administration 
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FIG. 5. Dose-effect curves for ICV and IM tertiary and quaternary 
naltrexone adfiainistered prior to 10.0 mg/kg morphine (IM): closed 
diamonds, IM tertiary naltrexone: open diamonds, ICV tertiary nal- 
trexone; closed triangles, IM quaternary naltrexone; open triangles, 
ICV quaternary naltrexone. All antagonist pretreatments were given 
ten minutes prior to morphine, except ICV quaternary naltrexone 
which was administered 60 minutes prior to morphine. The leftmost 
points represent the effects of 10.0 mg/kg morphine administered 
alone; the symbol on the left corresponds to the animals shown with 
the same symbol on the right. Ordinate: antagonism of morphine, 
expressed as a percent increase of morphine's suppressing effects 
(lYYb=effects of morphine alone (67-91% suppression of control 
rate); 101F~-saline control rate). Abscissa: pretreatment dose of 
antagonist (mg/kg). Other information as in Fig. 3. 
tively antagonized morphine were 0.1 mg/kg IM and 0.389 
mg/kg (180.0 p-g) ICV. A dose of 1.0 mg/kg IM antagonized 
completely the suppressing effects of 10.0 mg/kg morphine, 
whereas doses greater than 180.0 p-g tertiary naltrexone ICV 
did not produce additional antagonism. 
Up to a dose of 32.0 mg/kg IM or 0.069 mg/kg ICV (32.0 
p.g), quaternary naltrexone failed to antagonize the rate- 
suppressing effects of 10.0 mg/kg morphine IM (Fig. 5). 
Larger doses were not evaluated because they suppressed 
response rates to less than 30% of the control rate when 
administered alone (Fig. 3). 
D I S C U S S I O N  
The radiographic procedure used in this study for the 
periodic assessment of cannula patency allows for the incor- 
poration of ICV drug administration in long-term behavioral 
experiments. Although there is a report on the use of this 
radiographic procedure for evaluating cannula patency in 
primates [10], cannula placement is most often assessed post 
hoc by histological techniques. These techniques, however, 
have the disadvantage of not permitting one to determine the 
cannula location until the experiment has been completed. 
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and are, therefore, inappropriate for long-term behavioral 
experiments.  In the absence of  reliable in vivo procedures for 
assessing ICV cannula patency,  significant time and energy 
could potentially be invested in animals with improper can- 
nula placement. 
It has been suggested for the pigeon that leakage of cere- 
brospinal fluid (CSF) when the dummy cannula is removed 
indicates proper placement of the cannula into the ventricle 
[7]. Use of this criterion alone, however,  may result in a 
significant number of false-negative judgements of cannula 
patency. Leakage of CSF was observed periodically in the 
present study, but unambiguous positive x-rays were ob- 
tained with pigeons that never leaked CSF. The results ob- 
tained in 26 cannulated pigeons do not show a clear relation- 
ship between positive cannula placement and leakage of 
CSF. Although placement of the cannula tip into the lateral 
ventricle may not be important for all experiments (e.g., 
when lipophilic compounds which pass readily throughout 
the CNS are administered), there are undoubtedly situations 
in which the exact location of the cannula will influence the 
results that are obtained (e.g., hydrophilic, highly charged 
molecules which will, presumably,  not diffuse readily 
throughout the CNS). 
It has previously been shown that systemically- 
administered quaternary naltrexone fails to mimic the ac- 
tions of tertiary naltrexone in the pigeon. Quaternary nal- 
trexone did, however,  bind to opioid recognition sites and 
attenuate the effects of morphine in vitro [ 19]. The presumed 
profile of action of quaternary derivatives has, therefore, 
established them as ideal pharmacological probes for differ- 
entiating central and peripheral effects. In agreement with 
earlier reports [19] IM quaternary naltrexone was not an 
effective antagonist of morphine 's  behavioral effects in the 
pigeon. Furthermore,  despite its well-documented 
antagonist actions in vi tro,  albeit with 50-fold less affinity 
than tertiary naltrexone, ICV quaternary naltrexone did not 
antagonize the rate-suppressing effects of morphine. These 
data indicate, based upon the relative affinities of  tertiary 
and quaternary naltrexone in vitro [19], that doses of 
quaternary naltrexone which one would predict to be 
effective against morphine if the BBB is circumvented, 
exert rate-suppressing effects when administered 
ICV. The relative ability of tertiary and quaternary nal- 
trexone to diffuse from the ventricle through brain tissue 
to opioid receptors also may have contributed to the differ- 
ences observed in their abilities to antagonize morphine. 
Quaternization of naltrexone may prevent it from readily 
passing through brain tissue and, thus, ICV quaternary nal- 
trexone may only antagonize actions of morphine that are 
mediated periventricularly. The direct effects of quaternary 
naltrexone in suppressing responding, however, appeared to 
prevent it from antagonizing morphine under these experi- 
mental conditions. 
It has been suggested that the effectiveness of other 
opioid antagonists may also be limited by their direct effects 
on behavior [20]. Furthermore,  it has been shown that ICV 
quaternary naltrexone is an effective morphine antagonist in 
the rat [5,9], however neither of these studies employed rate 
of responding as a behavioral measure. Quaternary nap 
trexone might also antagonize some effects of morphine in 
the pigeon if a measure other than rate of responding were 
used. The ideal compound for differentiating central and pe- 
ripheral effects may be one which is unable to pass the BBB, 
but has the same affinity as the tertiary form for opiate 
recognition sites. 
The results obtained in the present study were in agree- 
ment with previous reports [9,18] which indicated that 
lipophilic opioid antagonists (i.e., naloxone and naltrexone) 
are approximately equipotent when administered ICV or 
systemically because they diffuse easily across the BBB. 
Naltrexone had a similar antagonist potency whether in- 
jected centrally or peripherally, and was little if any more 
potent in suppressing food-maintained responding when 
administered ICV. Furthermore,  the rapid offset of nal- 
t rexone 's  rate-suppressing effects when administered ICV 
indicate that it diffuses quickly out of the pigeon brain. This 
result contrasts with the long duration of  rate suppression 
produced by large doses of quaternary naltrexone, pre- 
sumably due to its inability to pass from the CNS to the 
periphery. It is believed that the rate-suppressing effects of 
opioid antagonists in non-dependent animals are not due to 
actions on opioid receptors,  although relatively little is 
known regarding the mechanism of action of antagonists in 
non-dependent animals. The procedure described herein may 
be particularly useful for comparing the mechanism(s) of ac- 
tion for the direct (i.e., rate-suppressing) effects of opioid 
antagonists in the CNS and periphery. 
Potency differences of 2-300 fold have been demon- 
strated for various effects produced by morphine when it is 
administered centrally or peripherally in rats [2, 3, 18] and 
monkeys (Gmerek, personal communication). Based upon 
potency relationships for morphine given by different routes 
of administration, it has been argued that the rate- 
suppressing effects of morphine in the rat are predominantly 
due to its effects on CNS opioid mechanisms [1]. Morphine 
may also suppress food-reinforced responding in the pigeon 
by central mechanisms, given that it was approximately 100 
times more potent in suppressing responding when adminis- 
tered ICV There may also be a peripheral component to 
morphine 's  rate-suppressing effects, given that tertiary nal- 
trexone was slightly more potent as an antagonist when ad- 
ministered systemically. However,  the lack of antagonism 
observed with systemically-administered quaternary nal- 
trexone argues against this possibility. The rate-suppressing 
effects of centrally-administered quaternary naltrexone pre- 
cluded an evaluation of possible antagonistic effects at larger 
doses, whereas systemically-administered quaternary nal- 
trexone was evaluated up to doses which one would predict, 
based upon the relative potencies of tertiary and quaternary 
naltrexone in vitro [19], to be effective in attenuating the 
actions of morphine. 
The cannula verification procedure reported herein has 
been used successfully in our laboratory for periodically 
assessing cannula patency in both pigeons and monkeys [10], 
and could likely be adapted for other species. This procedure 
may significantly contribute to behavioral pharmacology 
given the extensive use of the pigeon in drug studies and the 
paucity of reliable in ~'ivo cannula verification techniques. 
Although 73c~ of the cannulations were initially judged posi- 
tive, due to various factors, only 47% (9 of 19) of those 
animals were still positive after ten months of experimenta- 
tion. Additional experience in our laboratory with this pro- 
cedure now indicates that the success rate and longevity of 
ICV cannulae in pigeons has improved considerably. Fi- 
nally, the failure of  quaternary naitrexone to antagonize the 
effects of morphine suggests that the typical approach of 
comparing systemically-administered tertiary and 
quaternary naltrexone may not provide sufficient evidence 
for implicating central mediation of a particular behavioral 
effect. 
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